Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 2/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.63 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL5972612 | 0.99 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL4369589 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL4377553 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL22475009 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL14782966 | 0.92 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2533738 | 0.91 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2025-11-27 | — | — | US | claimed |
| EP-3368089-B1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA INC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12318489-B2 | Nanoparticle formulations for delivery of nucleic acid complexes | TRANSLATE BIO MA, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-12195750-B2 | Inducible CRISPR system expression and applications thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-01-14 | — | — | US | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| US-20180055869-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | TRANSLATE BIO MA, INC. (US) | 2018-03-01 | — | — | US | claimed |
| EP-3256592-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | TRANSLATE BIO MA, INC. (US) | 2017-12-20 | — | — | EP | claimed |
| WO-2017075038-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | RANA THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| WO-2016130963-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2016-08-18 | — | — | WO | claimed |
| EP-3033424-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | Rana Therapeutics, Inc. (US) | 2016-06-22 | — | — | EP | claimed |
| WO-2015023975-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | claimed |
| US-20150050738-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | US | claimed |
| US-20250376708-A1 | Method for mRNA Capping | INST PROCESS ENG CAS (CN) | 2025-12-11 | — | — | US | disclosed |
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3368089-B1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20080160580-A1 | Methods of nucleic acid amplification and sequencing | SOLEXA, INC | 2008-07-03 | — | — | US | disclosed |
| US-7115400-B1 | Methods of nucleic acid amplification and sequencing | SOLEXA LTD. (GB) | 2006-10-03 | — | — | US | disclosed |
| EP-1634963-A1 | Methods of nucleic acid amplification and sequencing | Solexa Ltd. (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1117827-B1 | METHODS OF NUCLEIC ACID AMPLIFICATION AND SEQUENCING | SOLEXA LTD (GB) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | HINT1 3379/4885NT5E 619/4885GSK3A 3905/4885 |
| US-12318489-B2 | Nanoparticle formulations for delivery of nucleic acid complexes | DIS3, SYNCRIP, EXOSC5 | HINT1 3379/4885NT5E 619/4885GSK3A 3905/4885 |
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | HINT1 3379/4885NT5E 619/4885GSK3A 3905/4885 |
| US-20180055869-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RNASE1, NSUN3, NSUN2 | HINT1 2896/4885NT5E 655/4885GSK3A 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.